Evommune ended development of EVO756 for atopic dermatitis after its Phase 2b trial missed every primary and secondary endpoint studied; its stock’s reported sale price was $13.08 per share. The company will continue evaluating EVO756 for migraine prevention and expects current cash, cash equivalents and investments to fund operations into 2029.

Key Highlights

  • The Phase 2b study evaluated oral EVO756 in a randomized, double-blind, placebo-controlled, dose-ranging design.
  • Evommune’s reported common-stock sale price was $13.08 per share on September 8.
  • The company expects current cash, cash equivalents and investments to support operations into 2029.

Evommune, Inc. (NYSE: EVMN) plans to cease development of EVO756 for moderate-to-severe atopic dermatitis after its Phase 2b trial did not meet its primary and secondary endpoints at any dose studied. The company’s common stock had a reported sale price of $13.08 per share on September 8, 2026.

EVO756 Atopic Dermatitis Trial Misses Endpoints

It used a randomized, double-blind, placebo-controlled, dose-ranging design over a treatment period followed by additional follow-up. Evommune said the study did not meet its primary and secondary endpoints across all doses evaluated. The company plans to cease EVO756 development in atopic dermatitis based on those results.

Migraine Program Continues

Evommune will continue evaluating EVO756 for migraine prophylaxis. The company’s current business plans, including revised clinical development plans, are expected to leave cash, cash equivalents and investments sufficient to fund operations into 2029. The company’s chief executive officer, Luis Peña, signed the document dated September 8, 2026.